Mr Chaloner (August 2001 JRSM, pp. 409±412), commenting on the use of chloroform in the Crimean War, suggests that the wounded who were transported to Scutari to have operations performed there would have been less likely to die as a result of anaesthesia than those who were operated upon in the ®eld soon after their injuries, because they would be less likely to be hypovolaemic (if they survived the journey) and better able to withstand the depressive effects of chloroform.
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In the of®cial report the ®gures for the administration of chloroform are poor and only a few deaths are recorded 1 . One young soldier having a minor operation became violent and almost certainly died of cardiac arrest due to ventricular ®brillation.
In the French ArmyÐmore than ten times the size of the British ArmyÐno deaths due to anaesthesia were reported in 25 000 cases; careful instructions about its administration were issued 2 . Since the time of Larrey, it was the custom to perform amputations as soon after injury as possible, because a recently wounded soldier fared better. The ambulances volantes allowed operations to be performed at or near to the front line. In the British Army, just over 1500 received chloroform 3 . At the beginning of the war there were no ambulances. For this and other reasons, amputations were not always performed as quickly and there is no evidence that the army surgeons received speci®c instructions in the use of chloroform.
The transport to Scutari, which took several days, could well have increased the chances of hypovolaemic shock and infection, and therefore of death, before or soon after arrival, as Mr Chaloner suggests. The report by Dr Adhiyaman and others (October 2001 JRSM, pp. 512±514) of renal failure after co-prescription of angiotensin converting enzyme (ACE) inhibitors and nonsteroidal anti-in¯ammatory drugs (NSAIDs), together with ®ndings on renal function in elderly heart failure patients 1 , should invoke even greater vigilance in the era following the RALES study (which reported survival bene®t from co-prescription of spironolactone and ACE inhibitors in heart failure). Already there are reports not only of deterioration in renal function but also of hyperkalaemia complicating co-prescription of ACE inhibitors, spironolactone, and NSAIDs 3,4 . Spironolactone aggravates the impairment of potassium excretion in renal failure. NSAIDs are liable to impair potassium excretion in their own right, because they can induce hyporeninaemic hypoaldosteroncelecoxib 7 , so these drugs may differ little in this respect from conventional NSAIDs. Perhaps the time has come for indiscriminate prescription of NSAIDs to be used as an indicator of clinical underperformance. , uses your respected journal as a forum for his own agenda of hate. As I understand it, Dr Summer®eld was not present when Professor Dolev allegedly made the statement attributed to him. It is unclear to me on what basis Dr Summer®eld allows himself the liberty to cast aspersions on the former head of the IMA ethics committee by attributing to him such a statement, which Professor Dolev vehemently denies having made. Dr Summer®eld's calumnies, and particularly his decision to publish them in a journal such as yours, lead us to believe that he is less interested in advancing human rights and more interested in slandering and condemning Professor Dolev, the IMA ethics committee and the State of Israel.
D D C Howat
We would expect a journal of your calibre to check the facts before you allow them to be printed, and not allow your publication, a medical and not political journal, to be used as a forum for the spewing of lies and vili®cation. The tone and substance of Dr Blachar's letter is sadly familiar to those who have attempted to engage the IMA on these issues over the years: the standard response (when one can be elicited) is that we are motivated by anti-Israeli, and by implication anti-semitic, sentiments. It is worth noting that, in the paper referred to above, Dr Forrest also cited a letter by Dr Blachar in the Israeli newspaper Ha'aretz of 15 November 1999. In it Dr Blachar failed to categorizè moderate physical pressure' as torture (which all human rights organizations have long since condemned as the of®cial euphemism for torture in Israel) and suggested that this might be a suitable response in a`ticking bomb situation' (his words).
This, then, is the quality of ethical leadership available to Israeli doctors. The case against the IMA is the most exhaustively documented of any since that brought fruitfully to bear against the Medical Association of South Africa during the apartheid era. 
Oesophageal cancer surgery
Mr Britton presents a plausible option for the reorganization of oesophageal cancer services (October 2001 JRSM, pp. 500±501). However, the ®nal sentence undermines the overall plan particularly with respect to the singlehanded or low-volume specialist. The proposed scheme, he says,`does not represent a threat to any specialist in the ®eld provided his or her results withstand local and national review'. A corollary of low caseload volume is that results will be unlikely to be amenable to meaningful statistical review. A large number of years of data will be needed, ensuring a long delay to closure of the audit loop. The way ahead is surely to review operators' processes rather than outcomes of care. Thus,
